Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Phase 1

Recruiting

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Transformed Chronic Lymphocytic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Small Lymphocytic Lymphoma
Recurrent Transformed Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions: Biological: Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563
Drug: Bendamustine
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Fludarabine
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2021-05-19

Last Posted Date: 2024-10-14

Lead Sponsor: Mayo Clinic

Target Recruit Count: 25

Registration Number: NCT04892277

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Phase 1

Recruiting

Conditions: Acute Lymphoblastic Leukemia, in Relapse
Pediatric ALL
Acute Lymphoblastic Leukemia, Refractory

Interventions: Biological: CD19-CAR(Mem) T-cells
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna
Device: CliniMACS
Procedure: Leukapheresis

First Posted Date: 2021-05-11

Last Posted Date: 2024-03-06

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 60

Registration Number: NCT04881240

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

Phase 2

Active, not recruiting

Conditions: Relapsed/Refractory Mantle Cell Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Brexucabtagene autoleucel

First Posted Date: 2021-05-10

Last Posted Date: 2024-08-14

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 90

Registration Number: NCT04880434

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 37 locations

GFRα4 CAR T Cells in MTC Patients

Phase 1

Recruiting

Conditions: Metastatic Medullary Thyroid Cancer
Recurrent Thyroid Gland Medullary Carcinoma

Interventions: Drug: single dose of CART-GFRa4 cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-05-07

Last Posted Date: 2024-06-26

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 18

Registration Number: NCT04877613

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia (AML)
Acute Lymphoid Leukemia (ALL)
Myelodysplastic Syndromes (MDS)

Interventions: Other: Personalized rATG (P-rATG)
Radiation: Hyper fractionated total body irradiation
Drug: Thiotepa
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Melphalan
Drug: GCSF
Drug: Fludarabine

First Posted Date: 2021-05-04

Last Posted Date: 2024-04-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 59

Registration Number: NCT04872595

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Itacitinib for the Prevention of Graft Versus Host Disease

Phase 1

Active, not recruiting

Conditions: Hematologic and Lymphocytic Disorder

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Itacitinib
Drug: Tacrolimus
Drug: Thiotepa

First Posted Date: 2021-04-26

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT04859946

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Phase 1

Recruiting

Conditions: Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Refractory Adult T-Cell Leukemia/Lymphoma
Recurrent Adult T-Cell Leukemia/Lymphoma
Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Mogamulizumab
Biological: Natural Killer Cell Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2021-04-19

Last Posted Date: 2024-01-31

Lead Sponsor: John Reneau

Target Recruit Count: 12

Registration Number: NCT04848064

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients

Phase 1

Recruiting

Conditions: Relapsed Large B-cell Lymphoma
High-grade B-cell Lymphoma
Refractory Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma (DLBCL)
Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Transformed Follicular Lymphoma (TFL)

Interventions: Biological: CRC01
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-04-08

Last Posted Date: 2021-05-03

Lead Sponsor: Curocell Inc.

Target Recruit Count: 91

Registration Number: NCT04836507

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1

Recruiting

Conditions: Relapsed or Refractory Acute Lymphoblastic Leukemia

Interventions: Genetic: ssCART-19 Cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-04-01

Last Posted Date: 2023-09-21

Lead Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Target Recruit Count: 18

Registration Number: NCT04825496

Locations: 🇨🇳
Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd., Shanghai, Shanghai, China

Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1

Active, not recruiting

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8

Interventions: Biological: Autologous Mesothelin-specific TCR-T Cells
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Bendamustine

First Posted Date: 2021-03-22

Last Posted Date: 2024-10-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 9

Registration Number: NCT04809766

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy